Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced a voluntary lock-up undertaking by its founder and chairman, Mr. Qiu Jiwan, and one of its controlling shareholders, Hangzhou Quanyi Investment Management Partnership. This move is intended to express confidence in the company’s long-term value and future prospects. The lock-up agreement involves not selling their respective shares, which represent approximately 4.50% and 18.01% of the company’s total issued share capital, for a year starting March 20, 2025.
More about Qyuns Therapeutics Co., Ltd. Class H
YTD Price Performance: 41.73%
Average Trading Volume: 67,333
Technical Sentiment Consensus Rating: Strong Buy
See more insights into 2509 stock on TipRanks’ Stock Analysis page.